Takeda Pharm Stock Price, News & Analysis

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) has achieved carbon neutrality in its value chain for fiscal year 2019. This milestone was reached through energy conservation, green energy procurement, and investment in verified carbon offsets. Takeda aims to reduce operational emissions by 40% by 2025 and achieve carbon neutrality by 2040. The company supports over 30 renewable energy projects across 12 countries, addressing 15 out of 17 UN Sustainable Development Goals. Recognized for its climate leadership, Takeda has been named on CDP’s 'A List' and Corporate Knights Global 100 Most Sustainable Corporations.

Takeda Pharmaceutical Company Limited (NYSE:TAK) has received recognition in the 2021 Access to Medicine Index, ranking sixth overall among 20 pharmaceutical companies. The company excelled in Governance of Access, R&D capacity, and health system strengthening. Notably, Takeda ranked first in Governance of Access and led the industry for R&D capacity building. Its initiatives focus on affordable access, assessed access strategies, and local healthcare programs, such as the Blueprint for Innovative Healthcare Access in Kenya and Rwanda, aimed at enhancing medicine accessibility.

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) provided a comprehensive update during the 39th Annual J.P. Morgan Healthcare Conference. CEO Christophe Weber highlighted Takeda's strong business resilience amid COVID-19 and outlined plans for revenue growth through an innovative pipeline, targeting JPY5 trillion ($47 billion) by FY2030. Key programs, including TAK-003 for dengue and TAK-755 for thrombotic thrombocytopenic purpura, are expected to contribute significantly to revenue. Takeda aims to maintain investment-grade credit ratings, with a focus on cost synergies and shareholder returns.

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is set to participate in the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021. The virtual presentation will take place at 5:20 p.m. ET and will feature CEO Christophe Weber. Investors and the public can access the live webcast here. A replay and downloadable slides will also be available on Takeda's website following the event.

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) has successfully concluded the sale of a non-core portfolio of 16 prescription products to Cheplapharm for $562 million. This divestment, originally announced in September 2020, aligns with Takeda's strategy to streamline its focus on key therapeutic areas including Gastroenterology and Oncology. Proceeds from the sale will be allocated towards reducing debt, aiming for a net debt/adjusted EBITDA ratio of 2x by 2023. Takeda has exceeded its $10 billion divestiture goal with a total of 11 deals worth approximately $11.6 billion since January 2019.

Takeda Pharmaceutical Company has agreed to divest a non-core portfolio of prescription pharmaceutical products in China to Hasten Biopharmaceutic Co., Ltd. for $322 million. This portfolio, which generated approximately $109.5 million in sales during FY2019, includes cardiovascular products like Ebrantil. The divestiture aligns with Takeda's strategy to focus on core therapeutic areas such as Gastroenterology and Oncology. Proceeds will be used to reduce debt and support long-term growth, with over 15 product approvals planned in China over the next five years.

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) announced FDA approval for the supplemental New Drug Application (sNDA) of ICLUSIG® (ponatinib) for adults with chronic-phase chronic myeloid leukemia (CML) who are resistant or intolerant to at least two prior kinase inhibitors. The updated regimen features a starting dose of 45 mg, reducing to 15 mg upon achieving ≤1% BCR-ABL1^IS. The approval is based on data from the OPTIC and PACE trials. The revised label is expected to optimize treatment for patients with resistant CML, providing significant clinical benefits.

Prime Therapeutics has secured an agreement with Takeda Pharmaceuticals for its hemophilia A treatment, ADVATE. This collaboration aims to evaluate clinical outcomes and costs associated with hemophilia A treatments, which have become increasingly expensive. The agreement introduces a health plan remuneration model linked to quantifiable medical costs from ineffective treatments under a total cost of care framework. Hemophilia A affects around 80% of the 18,000 people living with the disorder in the U.S., presenting an opportunity for improved patient and cost outcomes.